ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 698

External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients

Robyn T. Domsic1, Svetlana Nihtyanova2, Stephen R. Wisniewski3, Michael J. Fine4, C. Kent Kwoh5, Christopher P. Denton6 and Thomas A. Medsger Jr.7, 1Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Department of Rheumatology, Royal Free Hospital, Medical School, London, England, 3Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, 5School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 7Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality, risk assessment and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:   The ability to risk stratify patients for short term mortality is important in SSc patient care and clinical trial design; but there is no externally validated short term mortality model in early diffuse cutaneous systemic sclerosis (dcSSc). We have previously used a prospectively enrolled large American single center SSc databank to develop and internally validate a 4-factor risk stratification model for two year mortality.  Our objective was to externally validate this two year mortality model in a European population of early dcSSc Caucasian patients. 

Methods:   A large European single-center prospectively enrolled SSc databank was used to identify an inception cohort of adult early dcSSc seen for an initial visit between 2000 and 2006 to serve as the external validation cohort.  Patients were considered to have early dcSSc if their first visit occurred< 2 years after the first symptom attributable to SSc with skin thickening proximal to the elbows or knees.  Vital status was determined using the UK National Care Records Service.

We used a 4-factor model (age at first visit, gastrointestinal severity, skin thickness progression rate and presence of anemia) to calculate a total sum score (range of -1 to 8) and risk stratify patients into low, moderate and high risk for two year mortality in the original derivation and external validation cohort.  Multiple data imputations were used for missing data in the validation cohort.  Stratum-specific chi-squares were compared for the low, moderate and high risk groups.

Results:   Of 160 European early dcSSc patients, 110 were Caucasian, and formed the external validation cohort.   The validation cohort had a mean age of 51.2 ± 12.4 years, was 74% female and a mean modified Rodnan skin score (mRss) of 26.6 ± 8.1.  Median disease duration from first SSc symptom was1.02 years (IQR 0.78, 1.49), or 0.78 years (0.52, 1.17) from first non-Raynaud symptom.  There was no significant difference in age, gender, disease duration or mRss between the validation and derivation cohort.  At two years, 7.3% had died in the validation cohort, compared to 22.6% in the original derivation cohort (p=0.0005).   The stratum-specific comparison of mortality rates using this risk model are shown in Table 1.  There was no difference in prediction of low or moderate risk groups between the models. 

 

Table 1:  Comparison of risk class specific two-year mortality rates in the derivation and validation cohorts

Risk Class

(sum of points)

Derivation cohort

(n=252)

Validation cohort

(n=110)

p-value

 

total n

% who died

total n

% who died

 

Low (≤ 0)

63

1.6

33

3.0

0.64

Moderate (1-2)

108

14.8

61

8.2

0.21

High (3 ≤)

81

49.4

16

12.5

0.006

Conclusion:   We have now validated a two year mortality risk stratification model for early dcSSc patients in American and European cohorts.  In this external validation, the model accurately predicted those at low and moderate risk of death at two years from the first visit.  There was a significantly lower rate of death in the validation cohort, possibly related to the inclusion of only recent patients or differences in the underlying populations, which may have affected performance in the high risk group. This model may be used to risk stratify patients for short-term mortality.

 


Disclosure:

R. T. Domsic,
None;

S. Nihtyanova,
None;

S. R. Wisniewski,
None;

M. J. Fine,
None;

C. K. Kwoh,
None;

C. P. Denton,
None;

T. A. Medsger Jr.,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/external-validation-of-a-two-year-mortality-risk-prediction-rule-in-early-diffuse-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology